167 related articles for article (PubMed ID: 28566208)
1. Development of WNK signaling inhibitors as a new class of antihypertensive drugs.
Ishigami-Yuasa M; Watanabe Y; Mori T; Masuno H; Fujii S; Kikuchi E; Uchida S; Kagechika H
Bioorg Med Chem; 2017 Jul; 25(14):3845-3852. PubMed ID: 28566208
[TBL] [Abstract][Full Text] [Related]
2. Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling.
Fujii S; Kikuchi E; Watanabe Y; Suzuyama H; Ishigami-Yuasa M; Mori T; Isobe K; Uchida S; Kagechika H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127408. PubMed ID: 32738993
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
Nishida H; Sohara E; Nomura N; Chiga M; Alessi DR; Rai T; Sasaki S; Uchida S
Hypertension; 2012 Oct; 60(4):981-90. PubMed ID: 22949526
[TBL] [Abstract][Full Text] [Related]
4. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
[TBL] [Abstract][Full Text] [Related]
5. Kelch-like 3/Cullin 3 ubiquitin ligase complex and WNK signaling in salt-sensitive hypertension and electrolyte disorder.
Sohara E; Uchida S
Nephrol Dial Transplant; 2016 Sep; 31(9):1417-24. PubMed ID: 26152401
[TBL] [Abstract][Full Text] [Related]
6. Structural Development of Salicylanilide-Based SPAK Inhibitors as Candidate Antihypertensive Agents.
Fujii S; Kikuchi E; Suzuyama H; Watanabe Y; Ishigami-Yuasa M; Masuno H; Mori T; Isobe K; Uchida S; Kagechika H
ChemMedChem; 2021 Sep; 16(18):2817-2822. PubMed ID: 34109743
[TBL] [Abstract][Full Text] [Related]
7. The WNK-SPAK/OSR1 pathway: master regulator of cation-chloride cotransporters.
Alessi DR; Zhang J; Khanna A; Hochdörfer T; Shang Y; Kahle KT
Sci Signal; 2014 Jul; 7(334):re3. PubMed ID: 25028718
[TBL] [Abstract][Full Text] [Related]
8. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation.
Thastrup JO; Rafiqi FH; Vitari AC; Pozo-Guisado E; Deak M; Mehellou Y; Alessi DR
Biochem J; 2012 Jan; 441(1):325-37. PubMed ID: 22032326
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel SPAK Inhibitors That Block WNK Kinase Signaling to Cation Chloride Transporters.
Kikuchi E; Mori T; Zeniya M; Isobe K; Ishigami-Yuasa M; Fujii S; Kagechika H; Ishihara T; Mizushima T; Sasaki S; Sohara E; Rai T; Uchida S
J Am Soc Nephrol; 2015 Jul; 26(7):1525-36. PubMed ID: 25377078
[TBL] [Abstract][Full Text] [Related]
10. Regulation of with-no-lysine kinase signaling by Kelch-like proteins.
Uchida S; Sohara E; Rai T; Sasaki S
Biol Cell; 2014 Feb; 106(2):45-56. PubMed ID: 24313290
[TBL] [Abstract][Full Text] [Related]
11. Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy.
Mori T; Kikuchi E; Watanabe Y; Fujii S; Ishigami-Yuasa M; Kagechika H; Sohara E; Rai T; Sasaki S; Uchida S
Biochem J; 2013 Nov; 455(3):339-45. PubMed ID: 23981180
[TBL] [Abstract][Full Text] [Related]
12. WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension.
Brown A; Meor Azlan NF; Wu Z; Zhang J
Acta Pharmacol Sin; 2021 Apr; 42(4):508-517. PubMed ID: 32724175
[TBL] [Abstract][Full Text] [Related]
13. Effect of heterozygous deletion of WNK1 on the WNK-OSR1/ SPAK-NCC/NKCC1/NKCC2 signal cascade in the kidney and blood vessels.
Susa K; Kita S; Iwamoto T; Yang SS; Lin SH; Ohta A; Sohara E; Rai T; Sasaki S; Alessi DR; Uchida S
Clin Exp Nephrol; 2012 Aug; 16(4):530-8. PubMed ID: 22294159
[TBL] [Abstract][Full Text] [Related]
14. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1.
Moriguchi T; Urushiyama S; Hisamoto N; Iemura S; Uchida S; Natsume T; Matsumoto K; Shibuya H
J Biol Chem; 2005 Dec; 280(52):42685-93. PubMed ID: 16263722
[TBL] [Abstract][Full Text] [Related]
15. Activation of the thiazide-sensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1.
Richardson C; Rafiqi FH; Karlsson HK; Moleleki N; Vandewalle A; Campbell DG; Morrice NA; Alessi DR
J Cell Sci; 2008 Mar; 121(Pt 5):675-84. PubMed ID: 18270262
[TBL] [Abstract][Full Text] [Related]
16. [WNK-SPAK-SLC12A signal cascade is a new therapeutic target for hypertension].
Kikuchi E; Mori T; Uchida S
Nihon Rinsho; 2015 Sep; 73(9):1597-605. PubMed ID: 26394527
[TBL] [Abstract][Full Text] [Related]
17. Interactions with WNK (with no lysine) family members regulate oxidative stress response 1 and ion co-transporter activity.
Sengupta S; Tu SW; Wedin K; Earnest S; Stippec S; Luby-Phelps K; Cobb MH
J Biol Chem; 2012 Nov; 287(45):37868-79. PubMed ID: 22989884
[TBL] [Abstract][Full Text] [Related]
18. Regulation of OSR1 and the sodium, potassium, two chloride cotransporter by convergent signals.
Sengupta S; Lorente-Rodríguez A; Earnest S; Stippec S; Guo X; Trudgian DC; Mirzaei H; Cobb MH
Proc Natl Acad Sci U S A; 2013 Nov; 110(47):18826-31. PubMed ID: 24191005
[TBL] [Abstract][Full Text] [Related]
19. With no lysine L-WNK1 isoforms are negative regulators of the K+-Cl- cotransporters.
Mercado A; de Los Heros P; Melo Z; Chávez-Canales M; Murillo-de-Ozores AR; Moreno E; Bazúa-Valenti S; Vázquez N; Hadchouel J; Gamba G
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C54-66. PubMed ID: 27170636
[TBL] [Abstract][Full Text] [Related]
20. Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade.
Chiga M; Rafiqi FH; Alessi DR; Sohara E; Ohta A; Rai T; Sasaki S; Uchida S
J Cell Sci; 2011 May; 124(Pt 9):1391-5. PubMed ID: 21486947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
